The FLT3^N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.

ABSTRACT:

SUBMITTER: Joshi SK 

PROVIDER: S-EPMC10842343 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature